CERS

Company Overview — What Does CERUS CORP Do?

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California. CERUS CORP (CERS) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO William M. Greenman and employs approximately 290 people, headquartered in CONCORD, California. With a market capitalization of $359M, CERS is one of the notable companies in the Healthcare sector.

CERUS CORP (CERS) Stock Rating — Reduce (April 2026)

As of April 2026, CERUS CORP receives a Reduce rating with a composite score of 36.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CERS ranks #3,648 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CERUS CORP ranks #595 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CERS Stock Price and 52-Week Range

CERUS CORP (CERS) currently trades at $1.88. The stock lost $0.03 (1.6%) in the most recent trading session. The 52-week high for CERS is $2.96, which means the stock is currently trading -36.4% from its annual peak. The 52-week low is $1.12, putting the stock 67.9% above its annual trough. Recent trading volume was 771K shares, suggesting relatively thin trading activity.

Is CERS Overvalued or Undervalued? — Valuation Analysis

CERUS CORP (CERS) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.44x, versus the sector average of 2.75x. The price-to-sales ratio is 2.63x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, CERS trades at 69.58x EV/EBITDA, versus 6.34x for the sector.

At current multiples, CERUS CORP trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CERUS CORP Profitability — ROE, Margins, and Quality Score

CERUS CORP (CERS) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -25.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -7.4% versus the sector average of -33.1%.

On a margin basis, CERUS CORP reports gross margins of 47.0%, compared to 71.5% for the sector. The operating margin is -7.0% (sector: -66.1%). Net profit margin stands at -12.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 18.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CERS Debt, Balance Sheet, and Financial Health

CERUS CORP has a debt-to-equity ratio of 242.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.73x, suggesting adequate working capital coverage. Total debt on the balance sheet is $85M. Cash and equivalents stand at $16M.

CERS has a beta of 1.63, meaning it is more volatile than the broader market — a $10,000 investment in CERS would be expected to move 63.3% more than the S&P 500 on any given day. The stability factor score for CERUS CORP is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CERUS CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, CERUS CORP reported revenue of $134M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-16M. Gross margin was 47.0%. Operating income came in at $-9M.

In FY 2025, CERUS CORP reported revenue of $234M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-16M. Revenue grew 16.1% year-over-year compared to FY 2024. Operating income came in at $-9M.

In Q3 2025, CERUS CORP reported revenue of $36M and earnings per share (EPS) of $0.00. Net income for the quarter was $-20,000. Revenue grew 15.7% year-over-year compared to Q3 2024. Operating income came in at $1M.

In Q2 2025, CERUS CORP reported revenue of $37M and earnings per share (EPS) of $-0.03. Net income for the quarter was $-6M. Revenue grew 21.8% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, CERUS CORP has demonstrated a growth trajectory, with revenue expanding from $30M to $134M. Investors analyzing CERS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CERS Dividend Yield and Income Analysis

CERUS CORP (CERS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CERS Momentum and Technical Analysis Profile

CERUS CORP (CERS) has a momentum factor score of 59/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

CERS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CERUS CORP (CERS) ranks #595 out of 838 stocks based on the Blank Capital composite score. This places CERS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CERS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CERS vs S&P 500 (SPY) comparison to assess how CERUS CORP stacks up against the broader market across all factor dimensions.

CERS Next Earnings Date

No upcoming earnings date has been announced for CERUS CORP (CERS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CERS? — Investment Thesis Summary

The quantitative profile for CERUS CORP suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.

In summary, CERUS CORP (CERS) earns a Reduce rating with a composite score of 36.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CERS stock.

Related Resources for CERS Investors

Explore more research and tools: CERS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CERS head-to-head with peers: CERS vs AZN, CERS vs SLGL, CERS vs VMD.